Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday.

Novo Nordisk said second-quarter sales of its blockbuster Wegovy weight-loss drug soared 67% on year, despite waves of U.S. patients using generic unbranded versions of the drug.The Danish company last week slashed full-year guidance,

STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing challenge from U.S. giant Eli Lilly, as well as copycat versions of its own Wegovy obesity drug.